Follistatin-344 (FS-344) refers to one form of follistatin, a natural protein that binds and blocks myostatin, a signal that limits muscle growth. It is not FDA-approved, and no approved medicine in the United States contains it.
Follistatin is a glycoprotein, a protein with sugar groups attached. The follistatin gene produces more than one form of the protein. FS-344 is the name of one of these forms, which the body then processes into a shorter circulating version. Products labeled follistatin-344 are typically recombinant, meaning made in cell culture. Follistatin got its name because it was first identified by its ability to suppress follicle-stimulating hormone (FSH).
Follistatin binds members of the TGF-beta family of signaling proteins, including activin and myostatin, and stops them from acting on their receptors. Animals that lack working myostatin develop much larger muscles, which is why follistatin has drawn interest as a possible approach to muscle-wasting diseases.
The main human research on FS-344 did not use the protein itself. It used gene therapy: a modified, harmless virus (AAV1) carrying the FS-344 gene was delivered directly into thigh muscles so that the muscle cells would make follistatin.
In a phase 1/2a trial published in 2015 in Molecular Therapy, researchers at Nationwide Children's Hospital in Ohio, led by Jerry Mendell, gave this gene therapy to six men with Becker muscular dystrophy. Four of the six walked farther on a six-minute walk test afterward, two showed no change, and no adverse effects were reported. Related studies were registered in inclusion body myositis and Duchenne muscular dystrophy.
These were very small studies without a control group, and they tested a gene therapy. They do not describe recombinant follistatin protein sold online, which has not been tested in published human trials.
Current status: Not FDA-approved.
Follistatin-344 is not the active ingredient in any FDA-approved medicine, and no follistatin gene therapy has been approved. It does not appear in any category of the FDA's 503A nomination lists (as updated May 14, 2026) and is not on the 503A bulks list, so it does not meet the conditions for 503A compounding.
It is also not a dietary supplement. Products labeled "for research purposes only" or "not for human consumption" are not approved medicines, and the FDA has not reviewed their contents, purity or quality.
There are no published human safety data for recombinant follistatin-344 protein, and the FDA has not published a safety assessment of it. Follistatin also blocks activin, a signaling protein involved in reproduction and other body systems, and the effects of blocking it with an unapproved product have not been studied in people.
The World Anti-Doping Agency (WADA) 2026 Prohibited List names follistatin as an example of a myostatin-binding protein under class S4 (hormone and metabolic modulators). It is prohibited at all times, in and out of competition.
Peptide Labs does not sell this compound. This page is general information, not medical advice. We are not a pharmacy, we do not supply follistatin-344, and we do not point readers to anyone who does.
For personal medical questions, including questions about muscle weakness or muscle disease, the right person to ask is a licensed healthcare provider.
See the full list of compound profiles in the Peptide Guide. Related profiles: IGF-1 LR3 and TB-500. You can also read whether peptides are legal in the U.S.